Allocates capital across growth-stage technology and healthcare via direct equity and structured secondaries, with emphasis on revenue-generating startups and repeat founders. Matthew Riley brings operating experience from senior roles at software companies and has led deal sourcing, diligence and portfolio operations for institutional investors. Active in co-investments and follow-on rounds, the profile suits LPs seeking concentrated exposure to founder-led companies with operational engagement and exit-focused governance.
Allocates capital across growth-stage technology and healthcare via direct equity and structured secondaries, with emphasis on revenue-generating startups and repeat founders. Matthew Riley brings operating experience from senior roles at software companies and has led deal sourcing, diligence and portfolio operations for institutional investors. Active in co-investments and follow-on rounds, the profile suits LPs seeking concentrated exposure to founder-led companies with operational engagement and exit-focused governance.
Targets growth-stage technology and healthcare companies with repeat founders, prioritizing revenue-generating businesses and clear paths to liquidity. Capital allocation blends direct equity, structured secondaries and disciplined follow-ons to concentrate high-conviction positions while reserving capital for add-on rounds. Investment horizon is multi-year, exit-oriented with active operational engagement to accelerate go-to-market and unit economics. Underwriting emphasizes founder quality, defensible product-market fit, measurable revenue traction and governance that aligns incentives for scaling and exit.
Targets growth-stage technology and healthcare companies with repeat founders, prioritizing revenue-generating businesses and clear paths to liquidity. Capital allocation blends direct equity, structured secondaries and disciplined follow-ons to concentrate high-conviction positions while reserving capital for add-on rounds. Investment horizon is multi-year, exit-oriented with active operational engagement to accelerate go-to-market and unit economics. Underwriting emphasizes founder quality, defensible product-market fit, measurable revenue traction and governance that aligns incentives for scaling and exit.
| Trades 837 | Longs Won 590/837 70% | Profit Factor 16.97 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $236,405.71 |
| Average Win $60,795.29 | Best Trade (Jul 18) $4.57M | Sharpe Ratio -70.07 |
| Average Loss -$8,557.41 | Worst Trade (Jul 18) -$158,745.22 | Z-Score 13.74 (100%) |
| Commissions $0 | Avg. Trade Length 8m 1w 2d | Expectancy $40,329.2 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 19,231 | 17,308 | 15,385 | 13,462 | 11,538 | 9,615 | 7,692 | 5,769 | 3,846 | 1,923 |